Top Page
Luye Pharma Group
(OTC:2186)
Luye Pharma Group (2186) vs. iShares MSCI Hong Kong ETF (EWH)
Luye Pharma Group Business Overview & Revenue Model
Luye Pharma Group Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 6.06B | 6.14B | 5.98B | 5.20B | 5.54B | Gross Profit |
| 4.04B | 4.20B | 4.14B | 3.40B | 3.99B | EBIT |
| 1.15B | 887.44M | 1.21B | 386.99M | 1.42B | EBITDA |
| 1.79B | 2.08B | 1.81B | 906.88M | 1.88B | Net Income Common Stockholders |
| 471.89M | 532.61M | 604.81M | -144.78M | 706.59M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.50B | 6.11B | 5.54B | 5.51B | 5.41B | Total Assets |
| 29.61B | 25.49B | 24.25B | 22.58B | 20.63B | Total Debt |
| 10.32B | 8.42B | 9.10B | 9.49B | 9.98B | Net Debt |
| 5.38B | 5.18B | 6.78B | 7.05B | 6.12B | Total Liabilities |
| 13.86B | 11.96B | 13.21B | 13.47B | 12.53B | Stockholders Equity |
| 14.15B | 12.53B | 10.18B | 8.49B | 7.89B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | 430.23M | 490.14M | -1.36B | -486.43M | Operating Cash Flow |
| 0.00 | 1.60B | 1.65B | 182.37M | 1.03B | Investing Cash Flow |
| 0.00 | -1.42B | -1.66B | -3.44B | 138.20M | Financing Cash Flow |
| 0.00 | 841.60M | 54.15M | 1.88B | 253.98M |
Luye Pharma Group Technical Analysis
Luye Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $12.60B | 23.97 | 3.53% | ― | -3.12% | -12.71% | |
54 Neutral | $5.24B | 3.26 | -44.35% | 6.48% | 16.78% | -0.10% | |
| $11.91B | 20.51 | 13.20% | 2.46% | ― | ― | ||
| $1.31B | ― | -4.93% | 2.69% | ― | ― | ||
| €1.04B | 9.62 | 23.28% | 5.18% | ― | ― | ||
68 Neutral | HK$11.97B | 13.40 | 7.25% | 4.38% | -1.81% | -3.79% | |
66 Neutral | HK$12.62B | 23.70 | 5.88% | ― | -42.02% | -76.29% |
Luye Pharma Group Corporate Events
Luye Pharma Group Ltd. has announced its upcoming annual general meeting to be held on May 28, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of several directors, and the re-appointment of Ernst & Young as the company’s auditor. Additionally, the meeting will consider resolutions to authorize the board to manage the company’s share capital, including the issuance and transfer of shares.
Luye Pharma Group Ltd. has launched its Rotigotine Luye transdermal patch in the UK for treating Parkinson’s disease and restless legs syndrome. This launch marks the first generic transdermal patch in the UK that is bioequivalent to Neupro, offering a smaller size and lower drug load without sodium metabisulfite, a known allergen. The company plans to expand its availability to other countries, leveraging its manufacturing facility in Germany, which specializes in transdermal drug delivery. This move strengthens Luye Pharma’s commitment to CNS treatments and enhances its competitive position in the pharmaceutical industry.
Luye Pharma Group has announced that its innovative antidepressant, Ruoxinlin®, has been approved for marketing in Macao. This drug, which is China’s first independently developed Class 1 innovative chemical drug for MDD, has shown significant efficacy in reducing symptoms like anxiety and fatigue without adverse side effects. Since its launch in mainland China in 2022, Ruoxinlin® has gained clinical recognition and was recently included in China’s National Reimbursement Drug List, enhancing its accessibility and potential market impact.
Luye Pharma Group Ltd. announced that its Rivastigmine Twice Weekly Transdermal Patch has been approved for marketing in Japan for treating mild to moderate Alzheimer’s disease. This innovative patch, marketed as Rivaluen® LA Patch, offers a lower application frequency compared to existing daily patches, potentially improving patient adherence and reducing gastrointestinal side effects. The company has partnered with Towa Pharmaceutical Co., Ltd. to commercialize the patch in Japan, and it is also approved in Europe and China, with plans for further registrations in Southeast Asia and Latin America.
Luye Pharma Group Ltd. reported its annual financial results for the year ended December 31, 2024, highlighting a slight decrease in revenue by 1.3% to RMB6,061.4 million. Despite this, the company saw a 5.5% increase in EBITDA to RMB2,191.7 million and a 19.9% rise in profit before tax to RMB839.2 million. Net profit also increased by RMB105.9 million to RMB645.0 million. However, profit attributable to shareholders decreased by RMB60.7 million, and no dividend was proposed for the year. These results indicate a mixed financial performance, with improvements in certain profitability metrics but challenges in revenue growth and shareholder returns.
Luye Pharma Group Ltd. has announced a board meeting scheduled for March 28, 2025, to approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will determine the company’s financial performance and potential shareholder returns, impacting its market position and stakeholder interests.